Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.

Pronai W, Rosenkranz AR, Bock A, Klauser-Braun R, Jäger C, Pendl G, Hemetsberger M, Lhotta K.

Wien Klin Wochenschr. 2017 May;129(9-10):317-328. doi: 10.1007/s00508-016-1153-z. Epub 2017 Jan 13.

2.

EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.

Hemetsberger M, Oberbauer R, Erb H, Pronai W.

Wien Med Wochenschr. 2015 Oct;165(19-20):410-8. doi: 10.1007/s10354-015-0379-0. Epub 2015 Aug 25.

PMID:
26302869
3.

Darbepoetin alfa once every 2 weeks effectively maintained hemoglobin in dialysis patients in an observational study: Austrian cohort of ALTERNATE.

Pronai W, Neyer U, Barnas U, Wieser C, Jaeger C, Dekic D, Hemetsberger M, Rosenkranz AR.

Wien Med Wochenschr. 2014 Mar;164(5-6):109-19. doi: 10.1007/s10354-013-0256-7. Epub 2014 Jan 31.

PMID:
24482075
4.

Extended dosing of darbepoetin alfa in peritoneal dialysis patients.

Feriani M, De Meester JM, McMahon LP, Rottembourg JB, Bridges I, Farouk M, Pronai W.

BMC Nephrol. 2011 Mar 24;12:13. doi: 10.1186/1471-2369-12-13.

5.

An observational study of the effectiveness of darbepoetin alpha administered in dialysis patients once every 2 weeks for 12 months.

Rottembourg JB, Bridges I, Pronai W, Feriani M, McMahon LP, De Meester JM, Farouk M, Molemans B.

Clin Nephrol. 2011 Mar;75(3):242-50.

PMID:
21329635
6.

Results of a nationwide screening for Anderson-Fabry disease among dialysis patients.

Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G.

J Am Soc Nephrol. 2004 May;15(5):1323-9. Erratum in: J Am Soc Nephrol. 2004 Aug;15(8):1a. J Am Soc Nephrol. 2004 Sep;15(9):A4.

7.

Erythropoietin response to folic acid substitution.

Pronai W, Silberbauer K.

Nephron. 1999;81(3):353. No abstract available.

PMID:
10050095
8.

Folic acid supplementation improves erythropoietin response.

Pronai W.

Nephron. 1997;76(1):120. No abstract available.

9.

Folic acid supplementation improves erythropoietin response.

Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F.

Nephron. 1995;71(4):395-400.

PMID:
8587618

Supplemental Content

Loading ...
Support Center